Download MendeleyMechanism-based peroxiredoxin 3 inhibitors exploit a covalent warhead for cancer therapy.
Nelson, K.J., Smalley Jr., T.L., Messier, T., Gumpena, R., Gandhi, U., Milczarek, S., Habibovic, A., Hoffman, H., Gibson, V., Hondal, R.J., Lowther, W.T., Cunniff, B.(2025) Sci Adv 11: eady4492-eady4492
- PubMed: 41171914
- DOI: https://doi.org/10.1126/sciadv.ady4492
- Primary Citation of Related Structures:
9DEX - PubMed Abstract:
Covalent inhibitors that are approved and marketed drugs exploit a wide array of warheads and reactions with amino acid side chain-based nucleophiles. Thiostrepton (TS) inhibits the peroxidase activity of the mitochondrial antioxidant protein peroxiredoxin 3 by forming a covalent crosslink between the two active site cysteine residues. Peroxiredoxin 3 inactivation increases reactive oxygen species levels, induces cancer cell death in preclinical models, and shows promise in an ongoing clinical trial for malignant mesothelioma using direct pleural infusion. We report the identification of the minimal fragment of TS that contains tandem dehydro-alanine (DHA) moieties and maintains anticancer activity while losing interactions with three alternative targets of intact TS. Biochemical, kinetic, cellular, and structural studies demonstrate that this fragment is a mechanism-based peroxiredoxin inhibitor. These findings represent a promising start toward a pro-oxidant approach for cancer therapy. Moreover, the data support that the DHA moiety should be added to the covalent warhead arsenal.
- Department of Biochemistry, Center for Structural Biology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA.
Organizational Affiliation:
